Burden of tumor mutations, neoepitopes, and other variants are weak predictors of cancer immunotherapy response and overall survival

BACKGROUND: Tumor mutational burden (TMB; the quantity of aberrant nucleotide sequences a given tumor may harbor) has been associated with response to immune checkpoint inhibitor therapy and is gaining broad acceptance as a result. However, TMB harbors intrinsic variability across cancer types, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Wood, Mary A., Weeder, Benjamin R., David, Julianne K., Nellore, Abhinav, Thompson, Reid F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7106909/
https://www.ncbi.nlm.nih.gov/pubmed/32228719
http://dx.doi.org/10.1186/s13073-020-00729-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7106909/
https://www.ncbi.nlm.nih.gov/pubmed/32228719
http://dx.doi.org/10.1186/s13073-020-00729-2

Ejemplares similares